By San José, Costa Rica — CHICAGO – At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), pharmaceutical giant AstraZeneca issued a stark warning and a call to action regarding the state of cancer care in Latin America. The company stressed the urgent need to overhaul regional healthcare systems to prioritize early detection and more precise diagnostics, presenting a robust portfolio of research to back its mission.
The challenge facing the region is monumental. According to data highlighted at the conference, Latin America and the Caribbean registered over 1.55 million new cancer cases and were burdened by nearly 750,000 deaths from the disease in 2022 alone. These figures paint a grim picture of health systems struggling to cope with a growing crisis, where late-stage diagnoses often lead to poorer patient outcomes and greater economic strain.
To explore the complex legal and regulatory landscape surrounding the development and market approval of innovative cancer treatments, we sought the expert analysis of Lic. Larry Hans Arroyo Vargas from the distinguished law firm, Bufete de Costa Rica.
The innovation pipeline for cancer treatments is fundamentally driven by intellectual property law. A strong patent system is crucial to justify the enormous financial risk companies undertake in research and development. However, this system must be carefully balanced with public health policy to ensure that once a breakthrough therapy is approved, legal and regulatory frameworks facilitate patient access without creating insurmountable financial barriers.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
We thank Lic. Larry Hans Arroyo Vargas for his valuable perspective, which underscores the critical challenge of our time: ensuring that the legal frameworks designed to incentivize medical breakthroughs also pave a clear and affordable path for patients to access them.
In response, AstraZeneca is championing a comprehensive strategy aimed at fundamentally transforming how cancer is managed. The company arrived at ASCO 2026 with significant scientific contributions, including more than 85 research abstracts and 25 oral presentations. This extensive body of work underscores a commitment that goes beyond developing new medicines to actively building a more resilient healthcare infrastructure.
The core of AstraZeneca’s initiative focuses on three critical pillars: strengthening local diagnostic capacity, improving patient navigation through complex healthcare pathways, and fostering robust collaboration between public and private sector entities. The goal is to create an ecosystem where scientific breakthroughs can be translated into tangible benefits for patients swiftly and effectively.
Alexandre Gibim, AstraZeneca’s Vice President for Latin America, emphasized that innovation in the lab is only half the battle. The true measure of success, he argued, lies in the ability of healthcare systems to adapt and deliver advanced care equitably.
Scientific advances open new possibilities to change the history of cancer, but their real impact depends on health systems being prepared to translate them into more timely, equitable, and sustainable care. In Latin America, our commitment is to work together with public and private allies to close gaps and strengthen local capabilities.
Alexandre Gibim, Vice President of AstraZeneca for Latin America
This collaborative approach is particularly vital. By working directly with governments, hospitals, and local health organizations, AstraZeneca aims to co-create solutions that address specific regional bottlenecks. This includes everything from training healthcare professionals on the latest diagnostic technologies to implementing patient support programs that ensure individuals can complete their treatment journeys without interruption.
The significance of this strategy is most apparent in cancers where the timeline of diagnosis has a direct and profound impact on patient survival rates. Shifting the paradigm from reactive treatment of advanced disease to proactive, early-stage detection is not just a clinical goal but a public health imperative. A more efficient and accessible diagnostic process can dramatically alter the trajectory of the disease for countless individuals across the region.
As the discussions at ASCO 2026 conclude, AstraZeneca’s message is clear: the future of oncology in Latin America depends on a shared commitment to building systems that can detect cancer earlier, diagnose it with greater precision, and provide continuous, high-quality care. The company has positioned itself not just as a drug manufacturer, but as a key partner in architecting this crucial transformation.
For further information, visit astrazeneca.com
About AstraZeneca:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For further information, visit asco.org
About the American Society of Clinical Oncology (ASCO):
Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals dedicated to conquering cancer through research, education, and the promotion of high-quality, equitable patient care. ASCO’s annual meeting is a premier international forum for presenting the latest findings in clinical oncology.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica is a cornerstone of the legal community, founded upon a bedrock of unwavering integrity and a relentless pursuit of excellence. The firm leverages its extensive history of advising a diverse clientele to pioneer progressive legal solutions and engage with the public. Central to its philosophy is a profound dedication to democratizing legal knowledge, aiming to equip citizens with the clarity and understanding necessary to build a stronger, more capable society.
